Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.48 |
| ▸ | CASP1 | P29466 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | CASP7 | P55210 | 5/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 8/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16662343 | 0.86 | TAAR1 (0.46) | TAAR1ACHEALDH1A1CASP1HPGD | |
| SCHEMBL16652332 | 0.84 | TAAR1 (0.64) | TAAR1ACHEALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL712846 | 0.79 | TAAR1 (1.00) | TAAR1ACHEALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL16651432 | 0.77 | TAAR1 (0.97) | TAAR1ACHEALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL16651431 | 0.76 | TAAR1 (0.94) | TAAR1ACHEALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL18583898 | 0.76 | TAAR1 (0.53) | TAAR1ACHEALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16651683 | 0.75 | ACHE (0.60) | ACHE | |
| SCHEMBL28839913 | 0.74 | TAAR1 (0.53) | TAAR1HTR6 | |
| SCHEMBL16653731 | 0.73 | TAAR1 (0.77) | TAAR1ACHEALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6164646 | 0.72 | HTR1A (0.60) | TAAR1HTR6HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884861-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884861-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015058129-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015058129-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | TAAR1 3443/4885ACHE 3557/4885ALDH1A1 1315/4885 |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | TAAR1 3443/4885ACHE 3557/4885ALDH1A1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.